22:19 , Jul 19, 2018 |  BC Innovations  |  Translation in Brief

Public Funding Highlights: 2Q18

Public Funding Highlights: 2Q18 Selected developments and initiatives in 2Q18 from major sources of public funding including National Institutes of Health (NIH), the U.K.’s Medical Research Council (MRC), the Innovative Medicines Initiative (IMI) and the Canadian...
02:53 , Dec 8, 2017 |  BC Week In Review  |  Company News

Mero licenses AAT deficiency candidate from AstraZeneca

AstraZeneca plc (LSE:AZN; NYSE:AZN) granted Mereo BioPharma Group plc (LSE:MPH) an exclusive license and option to acquire AZD9668, an oral inhibitor of neutrophil elastase (ELANE; NE; HLE) which is in development to treat alpha-1 antitrypsin...